Dexmedetomidine Alleviates Rat Liver Histopathology during Experimental Sepsis

Abstract

Introduction: The Food & Drug administration has approved a new sedative dexmedetomidine, an imidazole compound with high affinity for adrenoceptors (alpha 2). for use in critical care units. Its other pharmacological effects include anxiolytic and lung ischemia reducing abilities. The liver being a vital organ for drug biotransformation and general body function may bear the brunt of dexmeditomidine effects. Prolonged use of dexmedetomidine in deeply sedated ccu patients who frequently suffer from sepsis requires scientific study of dexmedetomidine’s hepatic effects under pre clinical simulated circumstances before human studies can be conducted.

Aims and Objectives: The purpose of this study is to determine the histopathological changes of dexmedetomidine during septicemia in the preclinical rat model.

Place and Duration of study: Study was performed in the Animal House of Post Graduate Medical Institute, Lahore for 15 days.

Material and Methods: Our study agreement was analyzed and accepted by Ethical Committee at Post Graduate medical Institute, Lahore. Female rats weighing 200-250 grams for 7 weeks. One week before experiment animals were adapted in the lab maintained at 22 ± 2 C in a persistent 12 hrs. light/ dark cycle. Data was entered and analyzed using SPSS version 25. P-Value of < 0.05 was considered statistically significant.

Results: Control group did not show any change. Three mortalities were observed in toxic groups. Total scoring of pathological alterations in liver was done. Tissue scoring of control group was 0.4 ± 0.52. In septic group it was 4.5 ± 0.9 & 1.5 ± 0.80 in the dexmedetomidine groups. The mean of total scoring of variations of tissues showed a statistically significant difference.

Conclusion: It’s concluded that dexmedetomidine induced significant ameliorative changes in histology of rat liver during sepsis.